A Matter of Supply and Demand
Research - Ionis (IONS) gained about $1.2 billion in market value this week when a phase 3 study of nusinersen, the company’s antisense drug for Spinal Muscular … Continue Reading
PremiumSearch Results for gene therapy
What UniQure Needs for a Sea Change
Research - We’ve been discussing the potential for biotech to play some catchup to the broader market in our monthly webinars of late, and the move is … Continue Reading
Premium
ASCO Has Wrapped and EHA Is Underway
Research - ASCO has wrapped up and EHA is underway this weekend in Copenhagen. Lets take a quick look at the state of the markets as biotech … Continue Reading
Premium
Simply Sit on That Sarepta Trade, and More Updates
Research - The NASDAQ Biotech Index Fund (IBB) failed to break out from $285 last week (discussed two weeks ago in our webinar) and subsequently lost key … Continue Reading
Premium
Bluebird Bio’s CALD Data, And Other Updates
Research - Bluebird bio (BLUE) released interim data from the ongoing Phase 2/3 Starbeam Study (ALD-102) this morning and will present the results at AAN today, evaluating Lenti-D in cerebral adrenoleukodystrophy (CALD), known colloquially as Lorenzo’s Oil disease.
Premium
UniQure’s On To Something in Hemophilia B
Research - UniQure’s (QURE) AAV5-enabled AMT-060 looks good in its first human testing to date, with four of five Hemophilia B patients in the low-dose cohort fully … Continue Reading
Read now
Stocks Start the New Year on the Wrong Foot
Insights - Biopharma stocks are starting the year off on absolutely the wrong foot (though so is everything else), and last night’s SEVEN secondary stock offerings didn’t help Wednesday's price action.
Premium